• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4607200)   Today's Articles (1617)   Subscriber (49374)
For: Arbouw MEL, van Vugt JPP, Egberts TCG, Guchelaar HJ. Pharmacogenetics of antiparkinsonian drug treatment: a systematic review. Pharmacogenomics 2007;8:159-76. [PMID: 17286539 DOI: 10.2217/14622416.8.2.159] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]  Open
Number Cited by Other Article(s)
1
Castro ES, Santos-García D, de Deus Fonticoba T, Expósito Ruíz I, Tuñas Gesto C, Arribí MM. Causes and factors related to dopamine agonist withdrawal in Parkinson's disease. Brain Behav 2016;6:e00453. [PMID: 27247848 PMCID: PMC4864043 DOI: 10.1002/brb3.453] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/30/2015] [Revised: 01/09/2016] [Accepted: 02/03/2016] [Indexed: 11/06/2022]  Open
2
Titova NV. [A current view on dopamine receptor agonists in the treatment of Parkinson's disease]. Zh Nevrol Psikhiatr Im S S Korsakova 2015;115:76-83. [PMID: 26525820 DOI: 10.17116/jnevro20151159176-83] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
3
Džoljić E, Novaković I, Krajinovic M, Grbatinić I, Kostić V. Pharmacogenetics of drug response in Parkinson's disease. Int J Neurosci 2014;125:635-44. [PMID: 25226559 DOI: 10.3109/00207454.2014.963851] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
4
Rieck M, Schumacher-Schuh AF, Altmann V, Francisconi CL, Fagundes PT, Monte TL, Callegari-Jacques SM, Rieder CR, Hutz MH. DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients. Pharmacogenomics 2013;13:1701-10. [PMID: 23171335 DOI: 10.2217/pgs.12.149] [Citation(s) in RCA: 66] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]  Open
5
Kalinderi K, Fidani L, Katsarou Z, Bostantjopoulou S. Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease. Int J Clin Pract 2011;65:1289-94. [PMID: 22093536 DOI: 10.1111/j.1742-1241.2011.02793.x] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]  Open
6
Goldman JG, Vaughan CL, Goetz CG. An update expert opinion on management and research strategies in Parkinson's disease psychosis. Expert Opin Pharmacother 2011;12:2009-24. [PMID: 21635198 PMCID: PMC3152685 DOI: 10.1517/14656566.2011.587122] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
7
Arbouw MEL, Movig KLL, Egberts TCG, Poels PJE, van Vugt JPP, Wessels JAM, van der Straaten RJHM, Neef C, Guchelaar HJ. Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease. Eur J Clin Pharmacol 2011;65:1245-51. [PMID: 19669131 PMCID: PMC2778789 DOI: 10.1007/s00228-009-0708-6] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2009] [Accepted: 07/19/2009] [Indexed: 11/04/2022]
8
Goldman JG. New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges. PARKINSONS DISEASE 2011;2011:675630. [PMID: 21403865 PMCID: PMC3049364 DOI: 10.4061/2011/675630] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 10/15/2010] [Accepted: 01/12/2011] [Indexed: 12/01/2022]
9
Go CL, Rosales RL, Schmidt P, Lyons KE, Pahwa R, Okun MS. Generic versus branded pharmacotherapy in Parkinson's disease: does it matter? A review. Parkinsonism Relat Disord 2011;17:308-12. [PMID: 21367644 DOI: 10.1016/j.parkreldis.2011.02.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/28/2010] [Revised: 02/02/2011] [Accepted: 02/04/2011] [Indexed: 11/20/2022]
10
Arbouw MEL, Guchelaar HJ, Egberts TCG. Novel insights in pharmacogenetics of drug response in Parkinson’s disease. Pharmacogenomics 2010;11:127-9. [DOI: 10.2217/pgs.09.175] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]  Open
11
Arbouw MEL, Movig KLL, van Vugt JPP, Egberts TCG. Reply: long-term retention rate of pramipexole in the treatment of Parkinson’s disease. Eur J Clin Pharmacol 2009. [PMID: 19415250 PMCID: PMC2729986 DOI: 10.1007/s00228-009-0668-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
12
Liu YZ, Tang BS, Yan XX, Liu J, Ouyang DS, Nie LN, Fan L, Li Z, Ji W, Hu DL, Wang D, Zhou HH. Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients. Eur J Clin Pharmacol 2009;65:679-83. [PMID: 19396436 DOI: 10.1007/s00228-009-0658-z] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2009] [Accepted: 04/05/2009] [Indexed: 11/26/2022]
13
Bainbridge JL, Ruscin JM. Challenges of Treatment Adherence in Older Patients with Parkinson’s Disease. Drugs Aging 2009;26:145-55. [DOI: 10.2165/0002512-200926020-00006] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
14
Arbouw MEL, Movig KLL, Guchelaar HJ, Poels PJE, van Vugt JPP, Neef C, Egberts TCG. Discontinuation of ropinirole and pramipexole in patients with Parkinson's disease: clinical practice versus clinical trials. Eur J Clin Pharmacol 2008;64:1021-6. [PMID: 18626634 DOI: 10.1007/s00228-008-0518-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2008] [Accepted: 05/27/2008] [Indexed: 11/28/2022]
15
Di Napoli M, Shah IM, Stewart DA. Molecular pathways and genetic aspects of Parkinson's disease: from bench to bedside. Expert Rev Neurother 2008;7:1693-729. [PMID: 18052765 DOI: 10.1586/14737175.7.12.1693] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA